Brief: Clene Provides Update on ALS Clinical Development Meeting With FDA

Clene

21/12/2023 12:18

Dec 21 (Reuters) - Clene Inc.  CLNN.O :
    * CLENE PROVIDES UPDATE ON ALS CLINICAL DEVELOPMENT MEETING
WITH
FDA
    * CLENE INC.-FDA DETERMINED INITIAL FINDINGS ON BIOMARKER
NFL
REDUCTION FROM PHASE 2 PROGRAMS INSUFFICIENT TO SUPPORT
ACCELERATED APPROVAL AT THIS TIME
    * CLENE INC.: LOOKING FORWARD TO PROVIDING SUPPLEMENTAL DATA
FOR
FURTHER ENGAGEMENT WITH FDA IN FIRST HALF OF 2024
    * CLENE INC.: PLANS TO DEMONSTRATE HOW CNM-AU8'S MECHANISM
OF
ACTION IS LINKED TO REDUCTION IN NFL
    * CLENE INC.-ANTICIPATE LAUNCHING PHASE 3 ALS CONFIRMATORY
STUDY
IN 2024

Source text for Eikon:  ID:nGNXcgDx9J 
Further company coverage:  CLNN.O 

 ((Reuters.Briefs@thomsonreuters.com;))